KMBC: New drug shows promise for patients with common genetic heart condition

A new drug is showing tremendous promise for patients with a common genetic heart condition, called hypertrophic cardiomyopathy.

Dr. John Spertus, Clinical Director of Outcomes Research at Saint Luke's Mid America Heart Institute, led phase 3 of the EXPLORER-HCM Clinical Trial, which evaluated how the medication impacted patients' quality of life.

KMBC talked to Dr. Spertus about the exciting results and one participant, Gary Frericks, who says it has changed his life.

Watch the full story below.

Related Content

May. 19, 2021

EXPLORER-HCM Trial shows dramatic improvements in patients with common genetic heart condition, comes after decades of no new treatments
Saint Luke’s Mid America Heart Institute announced the results of a clinical trial that will impact patient care and improve quality of life for patients suffering from the most common genetic heart condition.
May. 14, 2021

Saint Luke’s Researchers Again Take Center Stage at Global Cardiology Conference
Saint Luke’s Mid America Heart Institute to share detailed trial results at American College of Cardiology Scientific Session May 15-17.
Dr. John Spertus, director of health outcomes research at Saint Luke's Mid America Heart Institute
May. 18, 2021

Saint Luke’s Innovation Week Profile: Dr. John Spertus
Dr. John Spertus didn't choose medicine; medicine chose him.